97
Oct 17 (Reuters) – Roche Holding AG: * ROCHE PRESENTS NEW PHASE III PIVOTAL DATA FOR VAMIKIBART IN UVEITIC MACULAR EDEMA (UME), A SERIOUS CAUSE OF VISION LOSS * ROCHE HOLDING AG – VAMIKIBART WELL TOLERATED WITH LOW INCIDENCE OF OCULAR AES Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
